I would have loved to have posed the question to KK, that whilst he believes MSC’s in their natural form to be safe, does he have any concerns that by manufacturing them via the iPSC process could trigger oncogenic transformation and hence create doubt about the produced cells tumorigenic quality?
- Forums
- ASX - By Stock
- CYP
- Ann: Sharewise Investor Presentation
Ann: Sharewise Investor Presentation, page-8
-
- There are more pages in this discussion • 31 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CYP (ASX) to my watchlist
|
|||||
Last
25.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $44.90M |
Open | High | Low | Value | Volume |
25.0¢ | 25.5¢ | 25.0¢ | $6.179K | 24.65K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 27654 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
26.0¢ | 4500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 27654 | 0.250 |
2 | 5562 | 0.245 |
3 | 104100 | 0.240 |
1 | 100000 | 0.235 |
2 | 15173 | 0.230 |
Price($) | Vol. | No. |
---|---|---|
0.260 | 4500 | 1 |
0.270 | 30000 | 1 |
0.280 | 3000 | 1 |
0.290 | 4125 | 2 |
0.295 | 183892 | 1 |
Last trade - 15.45pm 15/07/2024 (20 minute delay) ? |
Featured News
CYP (ASX) Chart |
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online